Physician profile
William D Soper
NPI 1053318691
$327.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $115.86 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $42.95 | 2019 | |
| Tei Biosciences INC | $27.52 | 2019 | |
| Becton, Dickinson and Company | $27.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2019 | |
| Davol INC. | $16.45 | 2019 | |
| Blue Earth Diagnostics | $15.50 | 2019 | |
| W. L. Gore & Associates, INC. | $13.31 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.06 | 2019 | |
| Olympus America INC. | $11.89 | 2019 | |
| Neotract INC. | $11.28 | 2019 | |
| Merck Sharp & Dohme LLC | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Soper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.